Related Experiment Videos
Inhaled steroids for neonatal chronic lung disease
1PICU, Addenbrookes Hospital, Hills Road, Cambridge, UK. paulalister@homesteadbarn.freeserve.co.uk
The Cochrane Database of Systematic Reviews
|July 25, 2000
Summary
Inhaled corticosteroids significantly improve extubation rates in premature infants with bronchopulmonary dysplasia (BPD). This treatment shows no increased risk of sepsis, offering a safer alternative for respiratory support.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Pharmacology
Background:
- Bronchopulmonary dysplasia (BPD) is a chronic lung disease common in premature infants.
- Systemic steroids offer temporary respiratory improvement but carry significant side effects.
- Inhaled corticosteroids present a potentially safer alternative with fewer adverse effects.
Purpose of the Study:
- To evaluate the efficacy of inhaled corticosteroids in reducing BPD-related morbidity.
- To compare inhaled corticosteroid treatment with placebo in infants with BPD.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) from Cochrane Database, literature, and expert contact.
- Inclusion criteria: infants with BPD treated with inhaled steroids versus placebo; exclusion: systemic steroid use.
- Analysis focused on ventilated and non-ventilated infant subgroups, assessing extubation rates and sepsis risk.
Main Results:
- Inhaled steroids markedly reduced the inability to extubate in ventilated infants (OR 0.12, 95% CI 0.03-0.43).
- Risk of sepsis was comparable between inhaled steroid and placebo groups (OR 0.72, 95% CI 0.21-2.43).
- Insufficient data prevented analysis of drug variations, duration, or efficacy in non-ventilated infants.
Conclusions:
- Inhaled corticosteroids administered for 1-4 weeks improve extubation rates in ventilated BPD infants without increasing sepsis risk.
- Efficacy of inhaled steroids in non-ventilated infants with BPD remains inconclusive due to limited data.